Table 1.
Summary of ongoing or completed phase 3 trials of immunotherapy combined with RT for NSCLC.
| NCT number | Study name | No. of patients | Inventions | Setting | Status |
|---|---|---|---|---|---|
| Early-stage NSCLC | |||||
| NCT03924869 | MK-3475-867/KEYNOTE-867 | 530 | Pembolizumab vs Placebo | Consolidation treatment after SBRT | Recruiting |
| NCT03833154 | PACIFIC-4 | 733 | Durvalumab vs Placebo | Consolidation treatment after SBRT | Recruiting |
| NCT04214262 | 480 | Atezolizumab vs Placebo | Induction/Consolidation treatment combined with SBRT | Recruiting | |
| Locally-advanced NSCLC | |||||
| NCT03519971 | PACIFIC-2 | 328 | Durvalumab vs Placebo | Consolidation treatment after concurrent chemoradiotherapy | Completed |
| NCT04597671 | NVALT28 | 170 | Durvalumab+PCI vs Durvalumab+observation | Consolidation treatment plus PCI after CRT | Recruiting |
| NCT04092283 | 660 | Concurrent CRT and Durvalumab vs CRT | Concurrent immunotherapy | Recruiting | |
| NCT04380636 | MK-7339-012/KEYLYNK-012 | 870 | Pembrolizumab+Olaparib vs Pembolizumab+Placebo | Consolidation treatment after CRT | Recruiting |
| NCT04026412 | CheckMate73L | 888 | Nivolumab+Ipilimumab vs Durvalumab | Consolidation treatment after CRT | Active, not recruiting |
| NCT04513925 | SKYSCRAPER-03 | 800 | Atezolizumab+Tiragolumab vs Durvalumab | Consolidation treatment after CRT | Recruiting |
| NCT03728556 | GEMSTONE-301 | 381 | Sugemalimab vs Placebo | Consolidation treatment after CRT | Completed |
| Advanced NSCLC | |||||
| NCT03774732 | NIRVANA-LUNG | 460 | Pembrolizumab+ChT+3D-CRT/SABR vs Pembrolizumab+ChT | First-line treatment | Recruiting |
| NCT03391869 | LONESTAR | 360 | Nivolumab+Ipilimumab+LCT vs Nivolumab+Ipilimumab | First-line treatment | Recruiting |
| NCT03867175 | 112 | Pembrolizumab+SBRT vs Pembrolizumab | Consolidation treatment after First-line systemic treatment | Recruiting | |
NSCLC, non-small cell lung cancer; RT, radiotherapy; CRT, chemoradiotherapy; SBRT, stereotactic body radiotherapy; PCI, prophylactic cranial irradiation; ChT, chemotherapy; SABR, stereotactic ablative radiotherapy; 3D-CRT, three dimensional conformal radiotherapy; LCT, local consolidation therapy.